Clinical Trials Directory

Trials / Completed

CompletedNCT03391284

Oral vs Intravenous Acetominophen for Postoperative Pain in Minimally Invasive Gynecologic Surgery

Preemptive Oral vs Intravenous Acetominophen for Postoperative Pain in Minimally Invasive Gynecologic Surgery: A Randomized Control Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
75 (actual)
Sponsor
Scripps Health · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypothesis: Postoperative pain will be equivalent in patients receiving preemptive oral acetaminophen as compared to patients receiving preemptive intravenous acetaminophen following minimally invasive benign gynecologic surgery. Primary outcome: • Difference in postoperative pain comparing preemptive use of PO versus IV acetaminophen o Mean Visual analog Scale (VAS) scores will be compared between the intervention group (PO acetaminophen) and the control group (IV acetaminophen). Secondary outcomes: * Difference in postoperative analgesic use between groups o Narcotics, NSAIDs * Difference in postoperative N/V between groups o Patient rated measure - none, mild, moderate, severe * Cost comparison between drugs

Detailed description

Hypothesis: Postoperative pain will be equivalent in patients receiving preemptive oral acetaminophen as compared to patients receiving preemptive intravenous acetaminophen following minimally invasive benign gynecologic surgery. Importance/significance: Adequate control of postoperative pain is important for patient satisfaction, adequate healing, and optimizing length of stay. The idea of preemptive analgesia (giving an analgesic prior to first skin incision to prevent sensitization of nerve pathways from the trauma of surgery) has been shown in many studies to improve postoperative pain. Intravenous acetaminophen has been found to be an effective agent when given preemptively, and many surgeons have adopted this practice. Unfortunately, the IV formulation of acetaminophen, unlike the oral formulation, is expensive as it is a relatively new drug. There are other oral analgesics (i.e. Celebrex) that have been found to be efficacious for postoperative pain control when given preemptively. There are no studies in gynecologic surgery, however, comparing the effectiveness of PO acetaminophen with IV acetaminophen. Given that PO acetaminophen is significantly cheaper than the IV formulation, this could result in cost savings for hospital systems while maintaining adequate patient comfort and satisfaction. Primary outcome: 1. Difference in postoperative pain comparing preemptive use of PO versus IV acetaminophen 2. Mean VAS scores will be compared between the intervention group (PO acetaminophen) and the control group (IV acetaminophen). Secondary outcomes: 1. Difference in postoperative analgesic use between groups - Narcotics, NSAIDs 2. Difference in postoperative N/V between groups 3. Patient rated measure - none, mild, moderate, severe 4. Cost comparison between drugs Methods: Patients scheduled to undergo minimally invasive benign gynecologic surgery will be randomized to one of two groups: Group 1: acetaminophen 1 gram PO 30min before surgery, then saline placebo IV after anesthesia induction but before skin incision Group 2: receives placebo pill PO 30min before surgery, then acetaminophen 1 gram IV after anesthesia induction but before skin incision Primary outcome: After surgery, postoperative pain measured at various time points by blinded investigator 2 hours postop, 4 hours postop, 24 hours postop Secondary outcomes: 1. Evaluate N/V - self-rated as none, mild, moderate, severe 2. Document amount of analgesic use (narcotic, NSAIDs) during hospital course 3. Compute cost comparison between medications Demographics to collect: Age, parity, BMI, procedure indication, pathology including uterine weight, procedure length

Conditions

Interventions

TypeNameDescription
DRUGacetominophenINTRAVENOUS
DRUGAcetaminophenORAL

Timeline

Start date
2016-02-01
Primary completion
2018-02-01
Completion
2018-02-01
First posted
2018-01-05
Last updated
2022-11-22

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03391284. Inclusion in this directory is not an endorsement.